Annual report [Section 13 and 15(d), not S-K Item 405]

REVENUES

v3.25.1
REVENUES
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUES

NOTE 10 – REVENUES

 

Disaggregation of Net Revenues

 

The Company’s net product revenues are summarized below:  

                 
   

Year ended  

December 31, 

  
    2024   2023  
Zembrace Symtouch   $ 8,546   $ 6,304  
Tosymra     1,548     1,464  
Total product revenues   $ 10,094   $ 7,768  

 

The Company recognized revenue beginning July 1, 2023, as a result of the acquisition of two marketed products.

 

Gross-to-Net Sales Accruals

 

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

 

Our provision for gross-to-net allowances was $4.5 million at December 31, 2024, of which $0.8 million was recorded as a reduction to accounts receivable and $3.7 million was recorded as a component of accrued expenses. Our provision for gross-to-net allowances was $2.9 million at December 31, 2023, $0.6 million of which was recorded as a reduction to accounts receivable and $2.3 million recorded as a component of accrued expenses.